Drug Trial Radar · NCT04539340
A Multi-cohort Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Oct 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Feb 28, 2020
Primary completion
Sep 8, 2020
Study completion Sep 8, 2020
Sponsor
- Lead sponsor
- AO GENERIUMIndustry
- Sponsor type
- Industry
- First posted
- Sep 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
It is a phase I open-label single-dose, dose-escalation cohort study to evaluate of the tolerance, safety, and pharmacokinetics of GNR-055 in healthy volunteers
Conditions
- Mucopolysaccharidosis Type II
- Metabolic Diseases
Interventions
GNR-055Biological
Single intravenous administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse EventsTime frame: Day 7 ± 1
Locations
1 site in 1 country. Site status is shown where the registry gives one.
FSAEI HE "I.M. Sechenov First Moscow State Medical University" of the Ministry of Health of Russian Federation
Moscow, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.